Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Off-target endothelial effects of ticagrelor versus clopidogrel or prasugrel in ACS patients
2014-004189-64Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor, clopidogrel and prasugrel in acute coronary syndrome (ACS) (3 arms), sponsored by Erasmus MC. Primary endpoint: Reactive hyperemia index at steady state. Started Jan 2015; status: completed.
02
Drugs
ticagrelorclopidogrelprasugrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2014-004189-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004189-64.